Strategies to modulate the immune system in breast cancer: Checkpoint inhibitors and beyond

Therapeutic Advances in Medical Oncology

Volumn 8, Issue 5, 2016, Pages 360-374

  Migali, Cristina ^a   Milano, Monica ^a   Trapani, Dario ^a   Criscitiello, Carmen ^a   Esposito, Angela ^a   Locatelli, Marzia ^a   Minchella, Ida ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

breast cancer; immune checkpoint inhibitor; immunotherapy

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MUCIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MUTATIONAL LOAD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

EID: 84981356896     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834016658423     Document Type: Review

References (56)

1. Adams S., Gray R., Demaria S., Goldstein L., Perez E., Shulman L., et al. (2014) Prognostic value of tumor-infiltrating lymphocytes in triple negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32: 2959-2967.
2. Bertucci F., Finetti P., Birnbaum D., Mamessier E., (2015) The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers. Oncoimmunology 5: e1085148.
3. Brignone C., Gutierrez M., Mefti F., Brain E., Jarcau R., Cvitkovic F., et al. (2010) First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8: 71-81.
4. Carson W., Shapiro C., Crespin T., Thornton L., Andersen B., (2004) Cellular immunity in breast cancer patients completing taxanes therapy. Clin Cancer Res 10: 3401-3409.
5. Cimino-Mathews A., Foote J., Emens L., (2015) Immune targeting in breast cancer. Cancer Network 29: 375-385.
6. Curigliano G., Romieu G., Campone M., Dorval T., Duck L., Canon J., et al. (2016) A phase I/II trial of the safety and clinical activity of a HER-2-protein based immunotherapeutic for treating women with HER-2-positive metastatic breast cancer. Breast Cancer Res Treat 156: 301-310.
7. Demaria S., Volm M., Shapiro R., Yee H., Oratz R., Formenti S., et al. (2001) Development of tumor infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy. Clin Cancer Res 7: 3025-3030.
8. Denkert C., Loibl S., Noske A., Roller M., Müller B., Komor M., et al. (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28: 105-113.
9. DePillis L., Eladdadi A., Radunskaya A., (2014) Modeling cancer-immune responses to therapy. J Pharmacokinet Pharmacodyn 41: 461-478.
10. Derer A., Deloch L., Rubner Y., Fietkau R., Frey B., Gaipl U., (2015) Radio-immunotherapy-induced immunogenic cancer cells as basis for induction of systemic anti-tumor immune responses: pre-clinical evidence and ongoing clinical applications. Front Immunol 6: DOI: 10.3389/fimmu.2015.00505.
11. Diab A., McArthur H., Solomon S., Sacchini V., Comstock C., Maybody M., et al. (2014) A pilot study of preoperative (PRE-OP), single-dose ipilimumab (IPI) and/or cryoablation (CRYO) in women (PTS) with early-stage/resectable breast cancer (ESBC). J Clin Oncol 32 (Suppl. 5): abstract 1098.
12. Dieci M., Criscitiello C., Goubar A., Viale G., Conte P., Guarneri V., et al. (2014) Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple negative breast cancer: a retrospective multicenter study. Ann Oncol 25: 611-618.
13. Dubovsky J., Beckwith K., Natarajan G., Woyach J., Jaglowski S., Zhong Y., et al. (2013) Ibrutinib is an irreversible molecule inhibitor of IKT driving a Th1-selective pressure in T lymphocytes. Blood 122: 2539-2549.
14. Emens L,. (2012) Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther 12: 1597-1611.
15. Emens L., Braiteh F., Cassier P., DeLord J., Eder J., Shen X., et al. (2015) Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Clin Cancer Res 75 (Suppl. 15): 2860.
16. Fecher L., Agarwala S., Hodi F., Weber J., (2013) Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 18: 733-743.
17. Gameiro S., Ardiani A., Kwilas A., Hodge J., (2014) Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology 3: e28643.
18. Generali D., Bates G., Berruti A., Brizzi M., Campo L., Bonardi S., et al. (2009) Immunomodulation of FOXP3+ regulatory T-cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 15: 1046-1051.
19. Ghiringhelli F., Menard C., Puig P., Ladoire S., Roux S., Martin F., et al. (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T-cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648.
20. Gibson J., (2015) Anti-PD-L1 for metastatic triple-negative breast cancer. Lancet Oncol 16: e264. DOI: 10.1016/S1470-2045(15)70208-1.
21. Kodumudi K., Woan K., Gilvary D., Sahakian E., Wei S., Djeu J., (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16: 4583-4594.
22. Kroemer G., Galluzzi L., Kepp O., Zitvogel L., (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31: 51-72.
23. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J., Cowey L., Lao C., et al. (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New Eng J Med 373: 23-34.
24. Lawrence M., Stojanov P., Polak P., Kryukov G., Cibulskis K., Sivachenko A., et al. (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
25. Le D., Uram J., Wang H., Bartlett B., Kemberling H., Eyring A., et al. (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372: 2509-2520.
26. Lehmann B., Bauer J., Chen X., Sanders M., Chakravarthy A., Shyr Y., et al. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: 2750-2767.
27. Limentani S., Campone M., Dorval T., Curigliano G., de Boer R., Vogel C., et al. (2016) A non-randomized dose-escalation phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER-2-overexpressing tumors. Breast Cancer Res Treat 156: 319-330.
28. Linch S., McNamara M., Redmond W., (2015) OX40 agonists and combination immunotherapy: putting the pedal to the metal. Front Oncol 5: 34. DOI: 10.3389/fonc.2015.00034.
29. Loi S., Michiels S., Salgado R., Sirtaine N., Jose V., Fumagalli D., et al. (2014) Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: the FinHER trial. Ann Oncol 25: 1544-1550.
30. Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., et al. (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31: 860-867.
31. Miles D., Roché H., Martin M., Perren T., Cameron D., Glaspy J., et al. (2011) Phase III multicenter clinical trial of the sialyl-TN (STN)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16: 1092-1100.
32. Mittendorf E., Ardavanis A., Symanowski J., Murray J., Shumway N., Litton J., et al. (2016) Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER-2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 30 2016. [Epub ahead of print].
33. Mittendorf E., Clifton G., Holmes J., Schneble E., van Echo D., Ponniah S., et al. (2014) Final report of the phase I/II clinical trial of E75 (nelipepimut-S) vaccine with booster inoculation to prevent disease recurrence in high risk creast cancer patients. Ann Oncol 25: 1735-1742.
34. Mittendorf E., Philips A., Meric-Bernstam F., Qiao N., Wu Y., Harrington S., et al. (2014) PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2: 361-370.
35. Mohebtash M., Tsang K., Madan R., Huen N., Poole D., Jochems C., et al. (2011) A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 17: 7164-7173.
36. Morgan R., Yang J., Kitano M., Dudley M., Laurencot C., Rosenberg S., (2010) Case report of a serious adverse event following the administration of T-cell transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18: 843-851.
37. Nanda R., Chow L., Dees E., Berger R., Gupta S., Geva R., et al. (2016) Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. [Epub ahead of print].
38. Nowak A., Robinson B., Lake R., (2002) Gemcitabine exert a selective effect om humoralimmune response: implication for chemo-immunotherapy. Canc Res 62: 2353-2358.
39. Park J., Melisko M., Esserman L., Jones L., Wollan J., Sims R., (2007) Treatment with autologus antigen-presenting cells activated with HER-2-based antigen lapuleucel-T: result of a phase I study in immunology and clinical activity in HER-2-overexpressing metastatic breast cancer. J Clin Oncol 25: 3680-3687.
40. Ribas A., Hodi F., Callahan M., Konto C., Wolchok J., (2013) Hepatotoxicity with combination of vemurafenib and ipilimumab. New Eng J Med 368: 1365-1366.
41. Rizvi N., Hellmann M., Snyder A., Kvistborg P., Makarov V., Havel J., et al. (2015) Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348: 124-128.
42. Sabatier R., Finetti P., Mamessier E., Adelaide J., Chaffanet M., Ali H., et al. (2015) Prognostic and predictive value of PD-L1 expression in breast cancer. Oncotarget 6: 5449-5464.
43. Salgado R., Denkert C., Demaria S., Sirtaine N., Klauschen F., Pruneri G., et al. (2015) The evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendation by an international TILs working group 2014. Ann Oncol 26: 259-271.
44. Sharma A., Koldovsky U., Xu S., Mick R., Roses R., Fitzpatrick E., et al. (2012) HER-2 pulsed dendritic cells can eliminate HER-2 expression and impact ductal carcinoma. in situ. Cancer 118, 4354-4362.
45. Shin D., Ribas A., (2015) The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 33: 23-35.
46. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J., Desrichard A., et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. New Eng J Med 371: 2189-2199.
47. Soliman H., (2013) Immunotherapy strategies in the treatment of breast cancer. Cancer Control 20: 17-21.
48. Stagg J., Allard B., (2013) Immunotherapeutic approaches in triple negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol 5: 169-181.
49. Stephens P., Tarpey P., Davies H., Van Loo P., Greenman C., Wedge D., et al. (2012) The landscape of cancer genes and mutational processes in breast cancer. Nature 486: 400-404.
50. Trappey F., Berry J., Vreeland T., Hale D., Sears A., Ponniah S., et al. (2013) Randomized phase II clinical trial of the anti-HER-2 (GP2) vaccine to prevent recurrence in high-risk breast cancer patients: a planned interim analysis. ASCO Meeting Abstract 31 (Suppl. 15): abstract 3005.
51. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., Boulamatsis D., (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87: 21-27.
52. Vassilaros S., Tsibanis A., Tsikkinis A., Pietersz G., McKenzie I., Apostolopoulos V., (2013) Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. Immunotherapy 5: 1177-1182.
53. Vatner R., Cooper B., Vanpouille-Box C., Demaria S., Formenti S., (2014) Combinations of immunotherapy and radiation in cancer therapy. Tumor Immunity (Frontiers in Oncology) 4: 325. DOI: 10.3389/fonc.2014.00325.
54. Vonderheide R., LoRusso P., Khalil M., Gartner E., Khaira D., Soulieres D., et al. (2010) Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T-cells. Clin Cancer Res 16: 3485-3494.
55. Zhang L., Dermawan K., Jin M., Liu R., Zheng H., Xu L., et al. (2008) Differential impairment of regulatory T-cells rather than effector T-cells by paclitaxel-based chemotherapy. Clin Immunol 129: 219-229.
56. Zhang P., Su D., Liang M., Fu J., (2008) Chemopreventive agents induce programmed death-ligand 1 (PD-L1) surface expression in breast cancer cells and promore PD-L1-mediated T-cell apoptosis. Mol Immunol 45: 1470-1476.